Skip to main content

Table 1 Disease and patient characteristics of thyroid specimens used in this study

From: A novel microfluidic device capable of maintaining functional thyroid carcinoma specimens ex vivo provides a new drug screening platform

No Tumour stage Patient age range (years) Tissue received
1 T2NXMX 40–50 M
2 T4aN1bMX 40–50 M
3 T3aNXMX 40–50 M
4 BG 50–60 B
5 T2NXMX 50–60 M,B
6 T3N1bMX 20–30 M
7 T4N0M0 80–90 M
8 T1aNXMX 60–70 M
9 BG 60–70 B
10 T2N1BMX 30–40 M,B
11 T3N1aMX 50–60 M
12 BG 30–40 B
13 BG 50–60 B
14 T4N0M1 50–60 M
15 T1aN1bMX 40–50 M
16 T1bNXMX 40–50 M,B
17 T3aNXMX 10–20 M
18 T3bN1aMX 40–50 M,B
19 T1NXMX 60–70 M,B
20 T1aNXMX 10–20 M
21 T3AN1bMX 30–40 M,B
22 T3aN1bM0 20–30 M
23 T1aNXMX 40–50 M,B
24 T3N1bM0 30–40 M,B
25 T2NXMX 70–80 M,B
26 T3aNXMX 60–70 M
27 T4aN1bMX 70–80 M,B
  1. BG Benign goitre, M Malignant tissue, B Benign tissue